Systemic Lupus ErythematosusCOLUPUSNCT06551389
Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU
An observational study of Systemic Lupus Erythematosus, run by University Hospital, Brest at 1 site in France.
Trial summary
Systemic lupus erythematosus is a complex systemicautoimmune disease that can affect most organs of the human body. Although they are many recommendations on the diagnosis and managment of SLE, diagnosis and therapeutic managment is still challenging. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Systemic Lupus Erythematosus
- How many people
- 300 participants
- Where
- 1 siteFrance
- Study dates
- 13 Oct 2020to Apr 2035
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients of the systemic lupus erythematous's multidisciplinary consultation at Brest CHRU
Who may be able to join
- Any patient over 18 years old of the multidisciplinary consultation
Who cannot join
- Opposition of patient
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sandrine JOUSSE-JOULIN, Rheumatologist contact
France1 site, 1 recruiting
- Recruiting
CHRU de Brest
Brest, 29609
Sandrine JOUSSE-JOULIN, sandrine.jousse@chu-brest.fr
About this study
Systemic lupus erythematosus is a complex systemicautoimmune disease that can affect most organs of the human body.
Although they are many recommendations on the diagnosis and managment of SLE, diagnosis and therapeutic managment is still challenging.
Read more
A pluridisciplinary consultation grouping rheumatologist, nephrologist, dermatologist, gynecologist, internist and immunologists has been set up in 2009 at the university hospital of Brest.
The investigators would like to identify in a longitudinal cohort the occurrence of the different clinico-biological and immunological patterns of systemic lupus erythematosus patients during our multidisciplinary consultation.
It is now crucial to organize a standardized data collection of these patients in order to evaluate our pratices, to be able to study the epidemiology of SLE in our city, and to promote this initiative at national and international level.
- Conditions
- Systemic Lupus Erythematosus
- Keywords
- autoimmune diseases, joint diseases, cutaneous systemic diseases, musculoskeletal diseases, arthritis, rheumatoid, rheumatic diseases, connectivite tissue diseases, immune system diseases
- Medical subject headings
- Lupus Erythematosus, Systemic, Autoimmune Diseases, Joint Diseases, Musculoskeletal Diseases, Arthritis, Rheumatic Diseases, Immune System Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Cohort data
Prevalence and incidence of the clinico-biological and immunological patterns in a longitudinal cohort present in the standardized collection book including evaluation of différents criteria aspects : SLICC criteria
Measured: one year
Cohort data
Prevalence and incidence of the clinico-biological and immunological patterns in a longitudinal cohort present in the standardized collection book including evaluation of différents criteria aspects : SLEDAI score
Measured: one year
Cohort data
Prevalence and incidence of the clinico-biological and immunological patterns in a longitudinal cohort present in the standardized collection book including evaluation of différents criteria aspects : SDI score
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2024
- Study start13 Oct 2020
- Primary completionApr 2035 (estimated)
- Study completionApr 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Systemic Lupus ErythematosusStudies of the same condition, open and under way.
- More trials run by University Hospital, BrestThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06551389
- Sponsor's protocol ID
- COLUPUS (2017.CE.10)
- Acronym
- COLUPUS
- Status last verified
- Jun 2026
- First submitted
- 20 Jun 2019
- Last updated
- 25 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU
- ClinicalTrials.gov ID
- NCT06551389
- Acronym / sponsor ID
- COLUPUS / COLUPUS (2017.CE.10)
- Conditions
- Systemic Lupus Erythematosus
- Keywords
- autoimmune diseases, joint diseases, cutaneous systemic diseases, musculoskeletal diseases, arthritis, rheumatoid, rheumatic diseases, connectivite tissue diseases
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- University Hospital, BrestUniversity, hospital or other
- Study start
- 13 Oct 2020 (actual)
- Primary completion
- Apr 2035 (estimated)
- Study completion
- Apr 2035 (estimated)
- First posted
- 13 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Systemic lupus erythematosus is a complex systemicautoimmune disease that can affect most organs of the human body.
Although they are many recommendations on the diagnosis and managment of SLE, diagnosis and therapeutic managment is still challenging.
A pluridisciplinary consultation grouping rheumatologist, nephrologist, dermatologist, gynecologist, internist and immunologists has been set up in 2009 at the university hospital of Brest.
The investigators would like to identify in a longitudinal cohort the occurrence of the different clinico-biological and immunological patterns of systemic lupus erythematosus patients during our multidisciplinary consultation.
It is now crucial to organize a standardized data collection of these patients in order to evaluate our pratices, to be able to study the epidemiology of SLE in our city, and to promote this initiative at national and international level.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients of the systemic lupus erythematous's multidisciplinary consultation at Brest CHRU
Key inclusion criteria (1 listed)
- Any patient over 18 years old of the multidisciplinary consultation
Key exclusion criteria (1 listed)
- Opposition of patient
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cohort data
Time frame: one year
Prevalence and incidence of the clinico-biological and immunological patterns in a longitudinal cohort present in the standardized collection book including evaluation of différents criteria aspects : SLICC criteria
Cohort data
Time frame: one year
Prevalence and incidence of the clinico-biological and immunological patterns in a longitudinal cohort present in the standardized collection book including evaluation of différents criteria aspects : SLEDAI score
Cohort data
Time frame: one year
Prevalence and incidence of the clinico-biological and immunological patterns in a longitudinal cohort present in the standardized collection book including evaluation of différents criteria aspects : SDI score
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2026.
Related trials for Systemic Lupus Erythematosus
RecruitingObservational study
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
RecruitingObservational study
Deciphering the Genetic Architecture of Autoimmune Diseases
Autoimmune Diseases
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
RecruitingPhase 1
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Lupus Erythematosus, Systemic
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sandrine JOUSSE-JOULIN, Rheumatologist contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Systemic Lupus Erythematosus, run by University Hospital, Brest at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sandrine JOUSSE-JOULIN, Rheumatologist (33 (0)2-98-34-72-64, sandrine.jousse-joulin@chu-brest.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cohort data (time frame: one year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026; AzTrials last refreshed its copy on 8 Nov 2026.